摘要
炎症性肠病(IBD)是一种病因不明的慢性、非特异性消化道炎症性疾病,其发病机制复杂,临床表现多样。生物疗法,特别是抗肿瘤坏死因子-α单抗从根本上改变了儿童IBD的治疗和病程。近年来,越来越多的生物制剂开始应用儿童IBD,现总结不同类型生物制剂在儿童IBD中的应用,阐述其作用机制、疗效、安全性、临床转换和联合应用等方面的最新研究进展,旨在提高儿科医师对IBD的优化治疗。
Inflammatory bowel disease(IBD)is a chronic,nonspecific inflammatory disease of the digestive tract with unknown etiology,complicated pathogenesis and diverse clinical manifestations.Biologic therapies,particularly anti-tumor necrosis factor-αantibodies,have fundamentally changed the treatment and course of IBD in children.In recent years,more biologics have been applied to pediatric IBD.This review summarizes the application of different biologics in pediatric IBD and elaborates on the latest research progress in their mechanism of action,efficacy,safety,clinical conversion and combined application,so as to improve the optimal treatment of IBD by pediatricians.
作者
邹标
刘圣烜
舒赛男
Zou Biao;Liu Shengxuan;Shu Sainan(Department of Pediatrics,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)
出处
《中华实用儿科临床杂志》
CAS
CSCD
北大核心
2024年第11期869-873,共5页
Chinese Journal of Applied Clinical Pediatrics
关键词
炎症性肠病
生物疗法
儿童
Inflammatory bowel disease
Biologic therapy
Child
作者简介
通信作者:舒赛男,Email:snshu@tjh.tjmu.edu.cn。
